Biopharma contributes to key global health discussions at WHA69
Find out here our take on the 69th World Health Assembly (WHA69) with some key relevant links included!
Read More
Pharmacovigilance of biotherapeutic medicines
A new study released in June 2016 identifying global case studies illustrating successes and challenges. A must read!
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2017-05-18 13:30:05
New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance
New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to ...
Read More2017-05-02 07:50:20
Fumie Griego joins International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as new Assistant Director General
IFPMA Director-General Thomas Cueni announced today that former PhRMA and Merck KGaA executive, Dr Fumie ...
Read More2017-04-17 18:00:39
Progress report on biopharmaceutical industry contributions to the global fight against Neglected Tropical Diseases (NTDs)
109 active R&D projects for NTDs, of which over 90% are collaborative involving over 50 ...
Read More2017-03-09 16:32:44
EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”.
Switching describes a physician’s decision to exchange one product that a patient receives for another. ...
Read More2017-02-28 07:57:57
IFPMA launches new policy principles and report on Rare Disease Day 2017 to benefit patients, healthcare and society
New set of policy principles outlines critical elements for a global framework on rare disease ...
Read More2017-02-10 09:30:19
IFPMA launches its 2017 facts & figures report
Geneva, 10 February 2017 – IFPMA has just published its 2017 facts & figures report ...
Read More2017-02-09 14:00:33
Leadership rotation at Fight the Fakes, the worldwide campaign to protect people from fake medicines
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its role as secretariat of Fight ...
Read More
Latest Statement
2017-05-27 10:35:37
WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines
Delivered by Laetitia Bigger, Director, Vaccines Policy IFPMA welcomes WHO’s efforts in developing a framework to avert shortages. While supply ...
Read More2017-05-25 16:20:07
WHO WHA 70 item 12.5 Review of the Pandemic Influenza Preparedness Framework
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More2017-05-24 17:33:48
WHO WHA 70 Item A70/12 Antimicrobial resistance
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More2017-05-23 06:56:40
IFPMA Statement on Appointment of Dr Tedros as Director-General of the World Health Organization
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More2017-05-11 08:48:32
IFPMA recommends WHO Fair Pricing Forum outcomes focus on feasible areas for collaboration where there is broad consensus
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More2017-03-27 15:42:51
Delivered at the 21st WHO Expert Committee on the Selection and Use of Essential Medicines
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More2017-02-16 08:32:05
G-FINDER Report 2016: The biopharmaceutical industry confirms its status as a significant funder of neglected disease R&D
Today the International Federation of Pharmaceutical Wholesalers (IFPW) begins its ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
Supply & demand: fighting falsified medicines on two fronts
As falsified medicines are debated this week at the World Health Assembly, IFPMA shares what the biopharmaceutical is doing to combat this risk to individual and public health. If there’s one place not to take a gamble, it’s on whether or not a medicine is real or falsified. Yet in the last weeks alone we’ve seen headlines pop up across the world as authorities...
Read More
Medicines are not luxury goods
I must admit I had been somewhat skeptical about the "WHO Fair Pricing Forum" held last week in Amsterdam. There were multiple reasons for my apprehension. One concern was clearly that the notion of “fair” is pretty much in the eye of the beholder, another was that none of the 300 expected participants had received any background documentation as the event date was coming...
Read More
Medical miracles call for “moonshot” mindsets
Over the course of my lifetime, human lifespan extended by three decades. Today we hope to lead healthy lives well into our 80s. Now I have to declare a vested interest in this topic: I am an aspiring role model for active and healthy ageing (I’m past 60 and look forward to working actively for a number of years to come). And I have also...
Read MoreLatest Tweets
@IFPMA @IFPMA @IFPMA @IFPMA 